Cambrex Expands Waltham Facility to Boost Peptide Therapy Manufacturing

Cambrexs New Manufacturing Destination in Waltham, Massachusetts

Announcement

Cambrex, a popular global contract development and manufacturing organization (CDMO), declared that Snapdragon chemistry cambrex company has extended its active pharmaceutical ingredient (API) facility in Waltham, Massachusetts, to contribute significantly to the development and manufacturing of peptide therapies. The expansion covering regions will help Cambrex to build on its credibility across certain areas and increase its business globally. The promising suite features advanced facilities and technologies that offer a dependable solution for peptide therapies. The Waltham will experience the satisfying facilities from Cambrex in the near future.

New GMP Manufacturing Suite Details

The new GMP manufacturing suite elevates the facility by 20% and consists of an ISO-7 cleanroom for preparative HPLC lyophilization and chromatography, as well as cold storage for raw materials and a separate product storage suite. On completion of this investment, the Snapdragon can now contribute to the peptide projects from development to GMP manufacturing, initiating solid-phase peptide synthesis (SPPS), hybrid or liquid-phase peptide synthesis (LPPS) approaches.

Snapdragons LPPS technology uses traditional API batch reactors and constant flow, eliminating the dependency on solid phase skilled reactors. This new LPPS technology materially diminishes solvent demand and the requirement for excessive reagents in comparison to standard solid-state peptide synthesis processes. The Cambrex has to date invested and continued with the same in R&D across the critical synthetic modalities, consisting of innovation for peptide manufacturing and new research on the application of AI for the utilization of oligonucleotide processes.

Views and Statements from the Company Leaders

General manager at Snapdragon Chemistry, Dr. Eric Fang, said, “We introduced this facility with the three-layer strategy in mind for the development of peptide drug candidates. We have begun with the automation of SPPS technology for proof-of-concept. We utilize the process using LPPS technology to leverage development and diminish the manufacturing cost. After which, we can transfer the process to our vast manufacturing facilities, like Charles City, Iowa, to produce materials in traditional large batch reactors, prominently minimizing the cost of those drugs.”

Chief scientific officer of Cambrex, Dr. Matt Bio, said, “The SPPS has secured its place. We generally use it in early development to reach the clinic and to initiate an evidence-based concept faster, but its not a scalable solution in cases where you want to supply a vast patient population. We introduced the LPPS process to accelerate all 1.4 million liters of capacity within a companys deliverables to peptide therapies.”